Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1889

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 12
Chunk 1889
---
formatted as Inline XBRL and contained in Exhibit 101).

*Filed
herewith

**Furnished
herewith

36

#Certain
of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). Denali Capital Acquisition
Corp. agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

^Certain
identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material
and (ii) information that the Registrant treats as private or confidential. Denali Capital Acquisition Corp. hereby undertakes to furnish
supplemental copies of the unredacted exhibit upon request by the SEC.

(1)Filed
as an exhibit to Amendment No. 1 to the Registration Statement on Form S-1 filed with the SEC on March 22, 2022 (File No. 333-263123).

(2)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on April 12, 2022 (File No. 001-41351).

(3)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on October 11, 2023 (File No. 001-41351).

(4)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on April 12, 2023 (File No. 001-41351).

(5)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on July 13, 2023 (File No. 001-41351).

(6)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on November 20, 2023 (File No. 001-41351).

(7)Filed
as an exhibit to the Annual Report on Form 10-K filed with the SEC on March 17, 2023 (File No.001-41351).

(8)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on July 10, 2024 (File No. 001-41351).

(9)Filed
as an exhibit to the Current Report on Form 8-K filed with the SEC on September 5, 2024 (File No. 001-41351).

(10